Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Key Inclusion Criteria: 1. Must have given written informed consent and be able to comply with study requirements 2. Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal. Males must be surgically sterile or, if engaged in sexual relations with a female of child bearing potential, the subject must be using an acceptable contraceptive method from the time of signing the informed consent form until at least a period of 13 weeks after the last dose of Study Drug (ISIS 696844 or placebo) 3. Well-demarcated Geographic Atrophy due to Age Related Macular Degeneration Key Exclusion Criteria: 1. Clinically-significant abnormalities in medical history 2. Diagnosis of primary or secondary immunodeficiencies of B lymphocyte function, splenectomy, glomerulonephritis or history of recurrent meningococcal disease 3. Diabetes mellitus or thyroid disease unless well controlled for a period of at least 3 months 4. Clinically-significant abnormalities in screening laboratory values 5. Unwillingness to be administered, or history of a serious reaction to protocol required vaccines 6. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B 7. History or presence of a disease other than AMD in study eye